An increasing number of cervical cancer screening programs are converting from cytology to primary HPV-based organized screening because of better clinical performance. HPV assays need to be clinically validated and comply with international guidelines to assure high quality of primary HPV-based screening.
Nevertheless screening also results in considerable overtreatment because many CIN2/3 lesions show spontaneous regression so a triage strategy is necessary and methylation can be used to support a wait-and-see policy in women with CIN2/3.
The webinar brings recent study data about the fully automated clinically approved NeuMoDx HPV Test Strip screening test and the prognostic value of FAM19A4/miR124-2 methylation to support conservative management of CIN2+ diagnosed women.